Serine arginine protein kinase 1 (SRPK1): a moonlighting protein with theranostic ability in cancer prevention
- 8 December 2018
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (1) , 1487-1497
Abstract
Serine/arginine protein kinase 1 (SRPK1); a versatile functional moonlighting protein involved in varied cellular activities comprised of cell cycle progression, innate immune response, chromatin reorganization, negative and positive regulation of viral genome replication, protein amino acid phosphorylation, regulation of numerous mRNA-processing pathways, germ cell development as well as inflammation due to acquaintances with many transcription factors and signaling pathways. Several diseases including cancer have been associated with dysregulation of SRPK1. The function of SRPK1 in cancer is contradictory and inexplicable because it acts as both tumor suppressor and promoter based on the type of cell and locale. Over expression of SRPK1 including its role has been recently narrated and associated with several cancers, which includes, lung, glioma, prostate and breast via dysregulated signals from the Akt/eIF4E/HIF-1/VEGF, Erk or MAPK, PI3K/AKT/mTOR, TGF-β, and Wnt/β-catenin signaling pathways. Therefore, SRPK1 has occurred as a promising and possible curative target in cancer. In recent years, few natural and synthetic SRPK1 inhibitors have been discovered. This review emphasizes and highlights the complicated connections between SRPK1 and oncogenic signaling circuits together with the possibility of aiming SRPK1 in the treatment of cancer.Keywords
Funding Information
- University Grants Commission (NFO-2015-17-OBC-GUJ-29274)
This publication has 101 references indexed in Scilit:
- SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling‐mediated tumorigenesis by enhancing β‐catenin biosynthesisEMBO Molecular Medicine, 2013
- Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYCCell Reports, 2012
- Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or ParadoxCancer Cell, 2012
- WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF SplicingCancer Cell, 2011
- Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor MicroenvironmentThe American Journal of Pathology, 2011
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- Tau splicing and the intricacies of dementiaJournal of Cellular Physiology, 2011
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- SR Proteins in Vertical Integration of Gene Expression from Transcription to RNA Processing to TranslationMolecular Cell, 2009
- Regiospecific Phosphorylation Control of the SR Protein ASF/SF2 by SRPK1Journal of Molecular Biology, 2009